Wednesday, June 10, 2026

Patent intelligence · CA

CA 2682039

PREPARATIONS COSMETIQUES VISANT A REDUIRE LA CELLULITE DISGRACIEUSE

granted A61K 31/ 4155 A IA61P 3/ 04 A IA61P 17/ 00 A IA61P/1700
Status granted
Pipeline programs 2
Years to expiry 2
Applicant portfolio 5
Patent details — CA 2682039
Jurisdiction
CA
Status
granted
Grant date
Oct 2, 2008
Expiration
Sep 27, 2028
CPC classes
A61K 31/ 4155 A I, A61P 3/ 04 A I, A61P 17/ 00 A I, A61P/1700
View on Google Patents ↗

Quick answer

CA 2682039 (PREPARATIONS COSMETIQUES VISANT A REDUIRE LA CELLULITE DISGRACIEUSE) is held by MENARINI FARMA IND [IT]. Status: granted. Granted Oct 2, 2008. Expires Sep 27, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K 31/ 4155 A I, A61P 3/ 04 A I, A61P 17/ 00 A I, A61P/1700, A61P/304

More from MENARINI FARMA IND [IT]

Related pharmaceutical patents in our USPTO index.

  1. IT 201700031902

    Composizione nutraceutica, dietetica e nutrizionale ad attività antiossidante.

    A MENARINI IND FARMACEUTICHE RIUNITE S R L · Expires Sep 18, 2038

    granted
  2. EP 1526849

    TOPISCHE ZUSAMMENSETZUNG ENTHALTEND KETOPROFEN STABILISIERT MIT SULISOBENZON

    MENARINI FARMA IND [IT] · Expires Apr 29, 2025

    expired
  3. AT E203027

    PENEMDERIVATE, DEREN HERSTELLUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN

    MENARINI FARMA IND [IT] · Expires Jul 10, 2021

    expired
  4. US 6150325

    Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical compositions

    MENARINI FARMA IND [IT] · Expires Nov 16, 2020

    expired

Frequently asked questions

What is US patent 2682039?

CA 2682039 (PREPARATIONS COSMETIQUES VISANT A REDUIRE LA CELLULITE DISGRACIEUSE) is held by MENARINI FARMA IND [IT]. Status: granted. Granted Oct 2, 2008. Expires Sep 27, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Who owns CA 2682039?

MENARINI FARMA IND [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.

When does CA 2682039 expire?

Our index shows an expiration date of Sep 27, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.